Latest Conference Articles

January 22nd 2016, 3:14pm

Gastrointestinal Cancers Symposium (ASCO GI)

The PD-1 inhibitor nivolumab (Opdivo) had an overall response rate of 14% with an acceptable safety profile in patients with gastric or gastroesophageal junction cancer.

January 22nd 2016, 1:58pm

Gastrointestinal Cancers Symposium (ASCO GI)

The PD-1 inhibitor pembrolizumab (Keytruda) elicited encouraging activity with mild adverse events as a treatment for patients with advanced PD-L1–positive esophageal carcinoma.

January 22nd 2016, 1:39pm

Gastrointestinal Cancers Symposium (ASCO GI)

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the CALGB 80802 study, which examined sorafenib versus sorafenib plus doxorubicin in patients with advanced hepatocellular carcinoma in the first-line setting.

January 22nd 2016, 12:51pm

Gastrointestinal Cancers Symposium (ASCO GI)

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses sequencing regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

January 22nd 2016, 10:58am

Gastrointestinal Cancers Symposium (ASCO GI)

The immune checkpoint inhibitor nivolumab demonstrated activity in patients with previously treated esophageal cancer.

January 21st 2016, 5:27pm

Gastrointestinal Cancers Symposium (ASCO GI)

Adding liposomal irinotecan to 5-fluorouracil and leucovorin reduced the risk of death by 25% for patients with metastatic pancreatic cancer following progression on a gemcitabine-based regimen.

January 21st 2016, 2:39pm

Gastrointestinal Cancers Symposium (ASCO GI)

Holly G. Prigerson, PhD, professor of Sociology in Medicine, Irving Sherwood Wright Professor in Geriatrics, Joan and Sanford I. Weill Department of Medicine, director, Center for Research on End of Life Care, Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses chemotherapy regimens for patients with advanced gastric cancer.

January 21st 2016, 2:35pm

Gastrointestinal Cancers Symposium (ASCO GI)

Amitabh Chak, MD, professor of Medicine, Gastroenterology, Case Western Reserve University School of Medicine, discusses challenges with screening patients for Barrett's esophagus and esophageal cancer.

January 19th 2016, 4:53pm

Gastrointestinal Cancers Symposium (ASCO GI)

Preoperative treatment with short-course radiation therapy plus 3 cycles of chemotherapy improved overall survival (OS) and was associated with fewer adverse events compared with standard chemoradiation for patients with locally advanced rectal cancer.

January 19th 2016, 3:29pm

Gastrointestinal Cancers Symposium (ASCO GI)

Everolimus reduced the risk of disease progression by at least 40% in patients with either gastrointestinal neuroendocrine tumors or NETs of unknown primary origin.

January 19th 2016, 3:23pm

Gastrointestinal Cancers Symposium (ASCO GI)

For patients with advanced midgut neuroendocrine tumors, the peptide receptor radionuclide therapy Lu-Dotatate continues to confer a major therapeutic benefit, reducing the risk of disease progression or death by 79% and signaling an improvement in overall survival as well.

January 11th 2016, 1:06pm

Genitourinary Cancers Symposium (ASCO GU)

Cory Abate-Shen, PhD, research faculty, Columbia Urology, Columbia University Medical Center, discusses the challenges of bladder cancer modeling.

January 11th 2016, 10:27am

Genitourinary Cancers Symposium (ASCO GU)

A selective class I oral histone deactylase inhibitor may increase the antitumor effect of high- dose interleukin-2 in renal cell carcinoma.

January 11th 2016, 10:25am

Genitourinary Cancers Symposium (ASCO GU)

Nivolumab’s second-line survival benefit in renal cell carcinoma was consistent across subgroups categorized by patient risk status, prior treatment, and degree of metastases, according to an update of the phase III CheckMate-025 trial.

January 11th 2016, 10:23am

Genitourinary Cancers Symposium (ASCO GU)

Daniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing the length of radiation treatments for patients with prostate cancer.

January 9th 2016, 5:36pm

Genitourinary Cancers Symposium (ASCO GU)

Hypofractionated radiotherapy demonstrated similar toxicity and was noninferior to standard radiation therapy for preventing PSA increases or disease recurrences for men with intermediate-risk prostate cancer.

January 9th 2016, 5:30pm

Genitourinary Cancers Symposium (ASCO GU)

Second-line treatment with atezolizumab (MPDL3280A) led to durable responses in patients with locally advanced or metastatic urothelial carcinoma.

January 9th 2016, 2:31pm

Genitourinary Cancers Symposium (ASCO GU)

Adding celecoxib and zoledronic acid to standard treatment extended survival in men with metastatic prostate cancer commencing first-line hormone therapy, according to updated data from the STAMPEDE trial.

January 9th 2016, 1:49pm

Genitourinary Cancers Symposium (ASCO GU)

The addition of the CTLA-4 inhibitor ipilimumab to cisplatin and gemcitabine did not significantly improve overall survival for patients with metastatic urothelial cancer.

January 9th 2016, 11:28am

Genitourinary Cancers Symposium (ASCO GU)

The investigational anti-PD-L1 antibody avelumab demonstrated antitumor activity with an acceptable safety profile in a phase Ib trial of patients with metastatic urothelial cancer refractory to standard therapy.